European Journal of Neurology · 2013 · 31 citations · 30 references
MedicineNeurologyPsychiatryMovement DisordersNeuropathologySubstance Abuse ToxicologyHeavy Metal NeurotoxicityManganese ToxicityManganese ToxicologyMotor DisordersParkinson DiseaseParkinsonian DisordersBasal Ganglia DamageBasal Ganglia HistologyBasal Ganglia ToxicityBlood Manganese BiomarkersBrain Manganese AccumulationGlobus Pallidus External SegmentMovement Disorder AssessmentUltrastructural Alterations
BACKGROUND AND PURPOSE: There is limited knowledge regarding the long-term outcome of the methcathinone/manganese-induced movement disorder. Our purpose was to define prognosis in intravenous methcathinone abusers affected by this distinctive disorder attributed to manganese (Mn) toxicity. Also, neuropathology from a globus pallidus region biopsy from a former user is reported. METHODS: Eighteen methcathinone abusers were categorized as active (five), discontinued (four) or former (nine) users. They were reassessed after a median of 32.5 months (range 3.4-59.6) clinically, on rating scales, and with MRI and blood Mn levels. The biopsy was examined ultrastructurally. RESULTS: Overall the group showed a slight tendency to deterioration at follow-up on clinical assessment of motor functioning, especially the active users. No significant change occurred on parkinsonian rating scale reassessment. Significant reduction in Mn levels occurred in former users, and decreased T1-weighted hyperintensity on basal ganglia MRI occurred in 3 of 4 former and 2 of 3 discontinued users, despite lack of clinical improvement. The biopsy consisted of white matter showing decompacted myelin sheaths and frequent abnormalities of mitochondria. CONCLUSIONS: No improvement in this Mn-induced movement disorder occurs after cessation of methcathinone abuse despite improvement of Mn blood levels and/or MRI abnormalities. Ultrastructural abnormalities in a former user confirm structural damage to white matter is associated with the disorder. Methcathinone/Mn toxicity is an important, disabling and permanent medical sequel of intravenous drug abuse in the former Soviet Union.
30
Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 86.9K citations
Margaret M. Hoehn, Melvin D. Yahr · Neurology · 1967 · 12K citations · Full text
Recent Developments in Parkinson's Disease
Howard I. Hurtig · Neurology · 1987 · 1.9K citations
Medicine, Neurology, Neuroscience +12
Irreversible motor impairment in young addicts ? ephedrone, manganism or both?
Katrin Sikk, Pille Taba, Sulev Haldre et al. · Acta Neurologica Scandinavica · 2007 · 664 citations
Medicine, Neurology, Toxicology +17
Una D. McCann, Dean F. Wong, Fuji Yokoi et al. · Journal of Neuroscience · 1998 · 605 citations · Full text
Medicine, Neuroscience, Pharmacology +17